Answers are grounded in this paper and cite their sources.
Case reports demonstrate topical timolol's effectiveness against granulomas in CAPD patients, suggesting a promising non-invasive treatment.
Exit‐site granuloma is a frequent and challenging complication in patients undergoing peritoneal dialysis, predisposing to exit‐site infections. Recent evidence suggests a potential role for topical timolol in promoting regression of granulomatous tissue. We report two patients on continuous ambulatory peritoneal dialysis who developed exit‐site granulomas. Both patients were treated with topical 0.5% timolol maleate ophthalmic solution applied locally to the exit site three times weekly as part of routine exit‐site care. Clinical response was monitored using serial photographs. Complete resolution of the granuloma was achieved within 3 weeks in one patient and within 2 months in the other. Neither patient developed local or systemic adverse effects, and no exit‐site infections occurred during treatment. Topical 0.5% timolol maleate may represent a safe, non‐invasive, and effective treatment option for peritoneal dialysis exit‐site granulomas. Larger studies are warranted to establish its efficacy in larger cohorts.
No takes yet. Share an insight, caveat, or question.
S et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: